Aurinia Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025, showing a return to profitability with an adjusted EPS of $0.16 and revenue of $62.5 million. The company highlighted strong sales growth of its drug LUPKYNIS, which generated $60 million in sales during the quarter. Aurinia also produced $12.4 million in operating cash flow, excluding restructuring costs. Separately, AIP reported a 28% year-over-year revenue increase to $16.5 million and record annual contract value (ACV) plus royalties of $66.8 million, up 15% year-over-year. AIP’s new FlexGen technology is being evaluated by 27 customers, with revenue recognition expected to begin in the second quarter. The company noted no impact from tariffs so far but cited potential headwinds from a weak dollar and unforeseen tariff effects as reasons for not raising guidance. Feedback on FlexGen has been positive, and AIP anticipates substantial bookings in the second half of the year.